Inverseon Announces Positive Phase IIa As...(target significant unmetmedical needs an...),Health

Date:1/29/2008

target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD

bill@inverseon.com

http://www.inverseon.com

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

'/>"/>

SOURCE Inverseon, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
3. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
4. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
5. InterCure Announces 100,000th RESPeRATE Unit Sold
6. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids